Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT)

66.85
Delayed Data
As of Oct 20
 -0.01 / -0.01%
Today’s Change
54.98
Today|||52-Week Range
141.00
-38.47%
Year-to-Date
Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study
Oct 13 / Zacks.com - Paid Partner Content
Non-Alcoholic Steatohepatitis 2017 Progress Update
Oct 12 / Zacks.com - Paid Partner Content
Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017
Oct 12 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close66.86
Today’s open67.47
Day’s range64.80 - 67.59
Volume1,565,575
Average volume (3 months)1,181,289
Market cap$1.7B
Dividend yield--
Data as of 3:59pm ET, 10/20/2017

Growth & Valuation

Earnings growth (last year)-75.10%
Earnings growth (this year)+16.78%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+796.87%
P/E ratioNM
Price/Sales107.40
Price/Book5.27

Competitors

 Today’s
change
Today’s
% change
MDCOMedicines Co-0.47-1.36%
AGIOAgios Pharmaceutical...-1.48-2.15%
SAGESAGE Therapeutics In...+0.58+0.92%
PBHPrestige Brands Hold...+0.11+0.23%
Data as of 4:02pm ET, 10/20/2017

Financials

Next reporting dateNovember 15, 2017
EPS forecast (this quarter)-$3.44
Annual revenue (last year)$25.0M
Annual profit (last year)-$412.8M
Net profit margin-1,654.56%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
Mark E. Pruzanski
Chief Operating Officer
Jerome B. Durso
Corporate headquarters
New York, New York

Forecasts